Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 3—March 2016

Middle East Respiratory Syndrome Coronavirus during Pregnancy, Abu Dhabi, United Arab Emirates, 2013

Asim MalikComments to Author , Karim Medhat El Masry, Mini Ravi, and Falak Sayed
Author affiliations: Mafraq Hospital, Abu Dhabi, United Arab Emirates

Cite This Article


As of June 19, 2015, the World Health Organization had received 1,338 notifications of laboratory-confirmed infection with Middle East respiratory syndrome coronavirus (MERS-CoV). Little is known about the course of or treatment for MERS-CoV in pregnant women. We report a fatal case of MERS-CoV in a pregnant woman administered combination ribavirin–peginterferon-α therapy.

As of June 19, 2015, a total of 1,338 laboratory-confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) and 475 associated deaths had been reported to the World Health Organization ( Payne et al. (1) reported stillbirth in a pregnant patient for whom MERS-CoV serologic testing was retrospectively positive, suggesting that surveillance for and treatment of MERS-CoV in pregnant women may differ from that for nonpregnant persons. We report a fatal case of MERS-CoV in a pregnant woman administered ribavirin–peginterferon-α therapy.

Case Report

On November 19, 2013, a 32-year-old woman residing in Abu-Dhabi, United Arab Emirates, sought medical care for fever and back pain of 4 days’ duration. The woman, a school teacher from Jordan, was 32 weeks pregnant; she reported 3 earlier pregnancies (2 live births) and no concurrent conditions. Emergency department (ED) and obstetric physicians suspected urinary tract infection. The patient declined admission but returned to the ED on November 22 with worsening fever, cough, and shortness of breath. She denied recent travel, sick contacts, or animal exposure within the previous 2 weeks. Lung examination results were within normal limits; the patient had no signs of active labor or fetal distress. Chest computed tomography scan revealed bilateral consolidation; pulmonary embolus was not seen.

The patient was admitted to the medical unit with suspected community-acquired pneumonia. Ceftriaxone and azithromycin were initiated. Her condition deteriorated, and on November 23, she was transferred to the intensive care unit (ICU) because of respiratory failure and hypotension. On November 24, acute respiratory distress syndrome developed, requiring respiratory and hemodynamic support. Empiric oseltamivir and vancomycin were added to the treatment regimen. Later that day, the baby was delivered by caesarean section because the patient was persistently hypoxemic while on maximal ventilator support. Transient improvement in oxygenation was noted after the delivery. The newborn, who was noted to be healthy and had Apgar scores of 6 and 8 at 1 and 5 minutes, respectively, had no contact with the mother after birth.

Nasopharyngeal aspirate samples were tested for influenza A(H1N1)pdm09 virus and MERS-CoV by real-time reverse transcription PCR (2), and multiple other laboratory and culture tests were conducted (Table). Most yielded negative results, but on November 25, the regional laboratory reported the MERS-CoV real-time reverse transcription PCR results were positive. Laboratory testing was done by qualitative assay, using the 2012 novel human CoV (human coronavirus–Erasmus Medical Center). The assay, performed according to a previously described method (3), contains reagents and enzyme for specific amplification of the region upstream of the envelope gene in the CoV genome.

On November 26, oral ribavirin (400 mg and 600 mg morning and evening, respectively) and subcutaneous peginterferon-α (180 µg 1×/wk) were initiated. On November 27, ribavirin was increased to 1,200 mg every 8 hours, and meropenem was begun. Septic shock developed in the patient, requiring maximal vasopressors and ventilator support. Despite intensive support, the patient’s condition continued to deteriorate; she died on December 2. Cultures of blood, tracheal aspirate, and urine obtained on the day of death showed no growth; a chest radiograph revealed improvement in pulmonary edema and consolidation.


Thumbnail of Timeline of clinical events in a pregnant patient with Middle East respiratory syndrome coronavirus (MERS-CoV) infection, Abu Dhabi, United Arab Emirates, 2013. ICU, intensive care unit.

Figure. Timeline of clinical events in a pregnant patient with Middle East respiratory syndrome coronavirus (MERS-CoV) infection, Abu Dhabi, United Arab Emirates, 2013. ICU, intensive care unit.

On November 21, MERS-CoV pneumonia developed in the patient’s husband. He had no concurrent conditions and fully recovered after receiving an antimicrobial drug regimen similar to his wife’s at a different facility. The husband subsequently reported that he and his wife had visited a cattle farm (goats, sheep, and camels) 10 days before becoming sick (4) (Figure) but had not consumed camel meat or milk. In addition, a mild cough without fever or other symptoms developed in the patient’s 8-year-old son; MERS-CoV PCR testing of nasopharyngeal aspirate from the boy was positive. He recovered uneventfully without intervention. The younger sibling and newborn remained asymptomatic and tested negative for MERS-CoV.

Patients infected with MERS-CoV typically show signs of respiratory illness (2) and sometimes diarrhea. Complications include acute renal failure and acute respiratory distress syndrome with shock. Immunocompromised patients may have atypical signs and symptoms. Furthermore, several issues are relevant to MERS-CoV and other infectious diseases acquired during pregnancy: 1) pregnancy is associated with immunologic changes that may alter susceptibility to and severity of infectious diseases; 2) the effects of infection upon the fetus are not fully understood; and 3) prophylaxis and treatment appropriate for the general population might not be appropriate for pregnant women (58). When the pregnant patient in our study sought medical care, she had atypical symptoms (fever and back pain, followed later by cough and shortness of breath). It is unclear if the delay in initiating antimicrobial therapy may have contributed to the fatal outcome.

MERS-CoV infection developed in 2 of the patient’s 4 other family members, an outcome compatible with the description of other small clusters among household members and close contacts. The spectrum of illness and symptomatology among the affected family is also noteworthy: the young child was mildly sick, whereas the pregnant mother died. This discrepancy in disease severity correlates with findings from other reports (9,10).

No MERS-CoV transmission was documented between the patient and hospital staff; thus, the staff’s use of contact and droplet precautions, including airborne precautions while performing aerosol-generating procedures, seems to have been effective (11,12). Of note, these precautions were implemented after the patient was transferred to the ICU. Thirty-six hospital personnel were screened: 11 ED, 13 obstetrics, 1 operating room, and 11 ICU staff. No symptoms developed, and all staff tested negative for MERS-CoV infection. The lack of cross transmission in the exposed healthcare workers before implementation of protective measures supports the benefit of using standard precautions and the fact that transmission of MERS-CoV between humans remains limited (13).

Although, MERS-CoV infection and pregnancy were a fatal combination for the patient in our study, virus shedding ceased in the patient during therapy with ribavirin and peginterferon-α. Knowledge about the use of these drugs is limited; thus, further studies are needed to understand the possible safety, efficacy, and optimal dosage and duration of this regimen. Few data exist regarding the use of ribavirin in pregnant humans; however, the drug is generally contraindicated in pregnancy (14,15) because of evidence of teratogenic and embryocidal effects in animal studies. The potential role of cyclosporine, intravenous immune globulin, and high-frequency ventilation for treatment of MERS-CoV during pregnancy needs evaluation.

After the baby was delivered, the patient showed transient improvement, with improved oxygenation, followed by progressive worsening of clinical status and death. It is unclear whether there is a pattern of delayed release of chemokines and activation of inflammatory cascades leading to delayed worsening of the clinical condition. The patient was maintained on broad-spectrum antibacterial drugs with excellent pharmacokinetics. All cultures and screening for resistant pathogens remained negative, making it unlikely that the patient succumbed to a superimposed bacterial infection.


Pregnant women who seek medical care for pneumonia, influenza-like illness, or sepsis on the Arabian Peninsula may benefit from screening for MERS-CoV to ensure early diagnosis and management of this sometimes fatal disease. The immunologic and chemokine response to the infection needs close examination to help define the potential therapeutic role of antiinflammatory agents in this disease.

MERS-CoV infection and pregnancy were a fatal combination in this case. Death occurred despite treatment with a combined ribavirin and interferon regimen and despite clearance of virus shedding and radiographic evidence of improvement at death. Thus, this regimen needs to be further studied in pregnant patients with MERS-CoV infection.

Dr. Malik is Chief of Infectious Diseases Service and the Chairman of Infection Control at Mafraq Hospital, Abu Dhabi, United Arab Emirates. His interests include healthcare-associated infections, multidrug-resistant pathogens, and emerging infectious diseases.



We thank the intensive care unit, obstetrics and gynecology, pharmacy, laboratory, and infection prevention teams who participated in the care of this patient.



  1. Payne  DC, Iblan  I, Alqasrawi  S, Al Nsour  M, Rha  B, Tohme  RA, Stillbirth during infection with Middle East respiratory syndrome coronavirus. J Infect Dis. 2014;209:18702. DOIPubMedGoogle Scholar
  2. Drosten  C, Seilmaier  M, Corman  VM, Hartmann  W, Scheible  G, Sack  S, Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis. 2013;13:74551. DOIPubMedGoogle Scholar
  3. Zaki  AM, van Boheemen  S, Bestebroer  TM, Osterhaus  AD, Fouchier  RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:181420. DOIPubMedGoogle Scholar
  4. Reusken  CB, Haagmans  BL, Muller  MA, Gutierrez  C, Godeke  GJ, Meyer  B, Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis. 2013;13:85966. DOIPubMedGoogle Scholar
  5. Jamieson  DJ, Regan  N, Theiler  RN, Rasmussen  SA. Emerging infections and pregnancy. Emerg Infect Dis. 2006;12:163843. DOIPubMedGoogle Scholar
  6. Wong  SF, Chow  KM, Leung  TN, Ng  WF, Ng  TK, Shek  CC, Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol. 2004;191:2927. DOIPubMedGoogle Scholar
  7. Stockman  LJ, Lowther  SA, Coy  K, Saw  J, Parashar  UD. SARS during pregnancy, United States. Emerg Infect Dis. 2004;10:168990. DOIPubMedGoogle Scholar
  8. Kourtis  AP, Read  JS, Jamieson  DJ. Pregnancy and infection. N Engl J Med. 2014;370:22118 and. DOIPubMedGoogle Scholar
  9. Assiri  A, Al-Tawfiq  JA, Al-Rabeeah  AA, Al-Rabiah  FA, Al-Hajjar  S, Al-Barrak  A, Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13:75261. DOIPubMedGoogle Scholar
  10. Memish  ZA, Zumla  AI, Al-Hakeem  RF, Al-Rabeeah  AA, Stephens  GM. Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med. 2013;368:248794. DOIPubMedGoogle Scholar
  11. Khabbaz  RF. Still learning from SARS. Ann Intern Med. 2013;159:7801. DOIPubMedGoogle Scholar
  12. Penttinen  PM, Kaasik-Aaslav  K, Friaux  A, Donachie  A, Sudre  B, Amato-Gauci  AJ, Taking stock of the first 133 MERS coronavirus cases globally—is the epidemic changing? Euro Surveill. 2013;18:20596. DOIPubMedGoogle Scholar
  13. WHO MERS-CoV Research Group. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr. 2013;5:pii:ecurrents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8. PMID 24270606
  14. Genetech, Inc. COPEGUS (ribavirin) tablets: highlights of prescribing information. Reference ID: 3004561 [cited 2015 Dec 8].
  15. Knowles  SR, Phillips  EJ, Dresser  L, Matukas  L. Common adverse events associated with the use of ribavirin for SARS in Canada. Clin Infect Dis. 2003;37:113942. DOIPubMedGoogle Scholar




Cite This Article

DOI: 10.3201/eid2203.151049

Table of Contents – Volume 22, Number 3—March 2016

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.



Please use the form below to submit correspondence to the authors or contact them at the following address:

Asim Malik, Mafraq Hospital, Infection Control Box 2951, Abu Dhabi, United Arab Emirates

Send To

10000 character(s) remaining.


Page created: February 18, 2016
Page updated: February 18, 2016
Page reviewed: February 18, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.